Alliances
The companies will develop therapies that target the complement cascade, a group of proteins known to play a role in autoimmune diseases.
Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company
Scientists at the University of Eastern Finland and the University of Oxford have shown that small RNA molecules occurring naturally in cells, i.e. microRNAs, are also abundant in cell nuclei.
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
Pherecydes Pharma and BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, announce the signing of a collaboration agreement.
In a deal-making spree, Genentech will team up with the small companies to take on various diseases, including multiple sclerosis.
Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the organizations made an announcement.
It’s no secret that artificial intelligence and machine learning play key roles in drug development. This week, multiple companies have advanced their AI programming.
PRESS RELEASES